April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Survival Benefit With GI-Based Adjuvant Chemotherapy Regimen in Mucinous Ovarian Cancer
February 5th 2019Data from a retrospective study suggests an adjuvant gastrointestinal-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD.
Read More
Expert Discusses Recent Advances With PARP Inhibitors in Ovarian Cancer
February 4th 2019In an interview with <em>Targeted Oncology</em> during the 2019 SGO Annual Winter Meeting, Shannon Westin, MD, discussed the advances seen with PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.
Read More
Questions Remain for Targeted Therapy Beyond PARP Inhibition in Ovarian Cancer
February 1st 2019Targeted therapy has effectively been established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the <em>BRCA</em>-mutated or homologous recombination deficient population, questions remain about how to best treat these patients, Ramez N. Eskander, MD, said at the 2019 SGO Annual Winter Meeting.
Read More
FDA Places Hold on Cervical Cancer Trial Evaluating AIM2CERV
January 25th 2019A partial clinical hold has been placed on the phase III AIM2CERV trial by the FDA, Advaxis, Inc. has announced.<sup>1</sup> The trial is evaluating the use of the investigational immunotherapy agent axalimogene filolisbac in high-risk locally advanced cervical cancer.
Read More
Looking Beyond PARP Inhibitors in Ovarian Cancer Treatment
January 24th 2019Despite all the positive data associated with PARP inhibitors for the treatment of patients with epithelial ovarian cancer who have known <em>BRCA</em> mutations, these agents are not curing patients, said Leslie M. Randall, MD, MAS, at the 2019 SGO Annual Winter Meeting.
Read More
Data Show Potential Survival Improvement With IO in Advanced Cervical Cancer
January 24th 2019Women with recurrent or metastatic cervical cancer who fail prior treatment are known to have a poor prognosis, but immunotherapy may extend their survival, according to a presentation by Deanna Teoh, MD, MS, at the 2019 SGO Annual Winter Meeting.
Read More
Expert Highlights Benefits of Genomic Testing in Ovarian Cancer
January 23rd 2019Genomic testing can help physicians in the treatment decision process for women with ovarian cancer. As more of these platforms become commercially available, however, physicians must also learn the similarities and differences between each of these tests.
Read More
Women With Select Subtypes of HPV at Higher Risk for Developing High-Grade Cervical Cancer
January 4th 2019Findings of a recent study suggest HPV testing should be incorporated into cervical cancer screening programs. The nested case-control Swedish study found that the presence of specific subtypes of HPV, namely HPV-16 and -18, were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.
Read More
Olaparib Meets Primary Endpoint in Confirmatory SOLO-3 Trial for Ovarian Cancer
January 4th 2019According to recently announced topline findings, the confirmatory phase III SOLO-3 trial of olaparib has met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in objective response rate in patients with <em>BRCA</em>-mutant ovarian cancer who have relapsed on at least 2 prior lines of therapy
Read More
Phase III Ovarian Cancer Study Terminated After Frontline Avelumab Falls Short
January 3rd 2019At a planned interim analysis of the phase III JAVELIN Ovarian 100 study evaluating frontline avelumab in ovarian cancer, an independent panel determined the study would not meet its primary endpoint of progression-free survival. The co-developers of the PD-L1 inhibitor have announced they will terminate the trial on this basis.
Read More
Dasatinib Receives FDA Approval for Pediatric Ph+ ALL
January 3rd 2019Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br />
Read More